Sun Pharma to set up manufacturing facility in Andhra Pradesh

Published On 2021-12-29 08:19 GMT | Update On 2021-12-29 08:19 GMT

Mumbai: Sun Pharmaceutical Industries Ltd. will be setting up a manufacturing facility in Andhra Pradesh, Sun Pharma's Founder, Dilip Shangvi and his team met with the Chief Minister of Andhra Pradesh, YS Jagan Mohan Reddy to discuss the progress of the pharmaceutical sector and the setting up an end-to- end manufacturing facility in the state.

Mr. Dilip Shangvi said "I am pleased with the Chief Minister's understanding of the opportunities and challenges facing the state, and added that the integrated development of the state was becoming clear as part of the Chief Minister's policy.

The Chief Minister explained to the team that the steps being taken by the government are for industrial progress and invited them to take advantage of this opportunity and invest in the state.

The Chief Minister also explained the steps being taken with the aim of integrated development in mind; highly transparent policies are being employed in industries. The state government is determined to make quality human resources available by making skills development/training accessible to all in the state.

The Chief Minister said that the state government was particularly focused on environmentally friendly policies. The Opening of this facility will lead to the creation of more jobs and will contribute to the enhancement of the industrial sector in the state. Post the meeting, it was revealed that enhancing the state's manufacturing capacity and the State Government's ongoing consultations with the relevant authorities, will lead to the company successfully establishing a new industry.

The Chief Minister told the team that the state would cooperate and support the industries.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma to set up manufacturing facility in Andhra Pradesh

Similar News